Papers/PMID:27270872
Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial.
Phytotherapy research : PTR2016The record
5 findings drawn from this paper, on 1 compound across 5 endpoints.
What it reported
How to read these marksWhat moved
5 findings
curcumin — decreases total cholesterol (TC)
PreliminaryGrade D, Preliminary. Non-human or in vitro only.Findingreplicated ×3“There were also significant reductions in body mass index and serum levels of total cholesterol, low-density lipoprotein cholesterol, triglycerides, aspartate aminotransferase, alanine aminotransferase, glucose, and glycated hemoglobin compared with the placebo group.”
Quoted verbatim from Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial.. - Study
- RCT
- Duration
- 8 weeks
- Dose
- amorphous dispersion curcumin formulation 500 mg/day (~70 mg curcumin) for 8 weeks
- Population
- adults with ultrasound-diagnosed nonalcoholic fatty liver disease
Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial.2016PMID:27270872
curcumin — decreases LDL cholesterol
PreliminaryGrade D, Preliminary. Non-human or in vitro only.Finding“There were also significant reductions in body mass index and serum levels of total cholesterol, low-density lipoprotein cholesterol, triglycerides, aspartate aminotransferase, alanine aminotransferase, glucose, and glycated hemoglobin compared with the placebo group.”
Quoted verbatim from Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial.. - Study
- RCT
- Duration
- 8 weeks
- Dose
- amorphous dispersion curcumin formulation 500 mg/day (~70 mg curcumin) for 8 weeks
- Population
- adults with ultrasound-diagnosed nonalcoholic fatty liver disease
Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial.2016PMID:27270872
curcumin — decreases triglycerides
PreliminaryGrade D, Preliminary. Non-human or in vitro only.Findingreplicated ×3“There were also significant reductions in body mass index and serum levels of total cholesterol, low-density lipoprotein cholesterol, triglycerides, aspartate aminotransferase, alanine aminotransferase, glucose, and glycated hemoglobin compared with the placebo group.”
Quoted verbatim from Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial.. - Study
- RCT
- Duration
- 8 weeks
- Dose
- amorphous dispersion curcumin formulation 500 mg/day (~70 mg curcumin) for 8 weeks
- Population
- adults with ultrasound-diagnosed nonalcoholic fatty liver disease
Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial.2016PMID:27270872
curcumin — decreases glycated haemoglobin (HbA1c)
PreliminaryGrade D, Preliminary. Non-human or in vitro only.Findingreplicated ×1“There were also significant reductions in body mass index and serum levels of total cholesterol, low-density lipoprotein cholesterol, triglycerides, aspartate aminotransferase, alanine aminotransferase, glucose, and glycated hemoglobin compared with the placebo group.”
Quoted verbatim from Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial.. - Study
- RCT
- Duration
- 8 weeks
- Dose
- amorphous dispersion curcumin formulation 500 mg/day (~70 mg curcumin) for 8 weeks
- Population
- adults with ultrasound-diagnosed nonalcoholic fatty liver disease
Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial.2016PMID:27270872
curcumin — decreases alanine aminotransferase
PreliminaryGrade D, Preliminary. Non-human or in vitro only.Findingreplicated ×3“There were also significant reductions in body mass index and serum levels of total cholesterol, low-density lipoprotein cholesterol, triglycerides, aspartate aminotransferase, alanine aminotransferase, glucose, and glycated hemoglobin compared with the placebo group.”
Quoted verbatim from Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial.. - Study
- RCT
- Duration
- 8 weeks
- Dose
- amorphous dispersion curcumin formulation 500 mg/day (~70 mg curcumin) for 8 weeks
- Population
- adults with ultrasound-diagnosed nonalcoholic fatty liver disease
Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial.2016PMID:27270872